Videos

Integrating PD-L1 Testing and Practical Implications for DFLOT Adoption

ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD

January 5th 2026

Experts discuss the importance of PD-L1 testing in treatment decisions for gastric cancer, emphasizing personalized approaches and improved patient outcomes.

Unmet Clinical Needs Driving Early Intervention in High-Risk Smoldering Multiple Myeloma

ByLarry Anderson, MD, PhD,Caitlin Costello, MD,Laahn Foster, MD

January 5th 2026

Early intervention in myeloma treatment addresses critical patient needs, highlighting new trial data and the importance of tailored therapies for better outcomes.

Comparing the Approved BCMA Bispecifics: Efficacy, Toxicity, and Treatment Burden

BySundar Jagannath, MBBS,Ajay Nooka, MD, MPH, FACP,Mohan Krishnamachary, MD,Nisha Joseph, MD,Donna Catamero, MSN, ANP-BC, OCN, CBCN

January 5th 2026

Explore the latest advancements in bispecific antibodies for treating BCMAs, highlighting their efficacy, administration frequency, and toxicity profiles.

Practical Implementation of Oral HMAs in MDS/CMML: Safety, Monitoring, and Coordination

ByAmer Zeidan, MBBS ,Ralph V. Boccia, MD, FACP ,Salman Fazal, MD ,Susan Granato, CRNP ,Aditi Shastri, MBBS

January 5th 2026

Explore the differences between bispecific antibodies and CAR T-cell therapy, highlighting their unique benefits and administration processes.

Insights into RWO 1L lupatercept vs 2L ESA

BySaulius Girnius, MD,Jamie Koprivnikar, MD,Aditi Shastri, MBBS,Brittany Ragon, MD,Jamile Shammo, MD, FASCP, FACP,Michael Haddadin, MBBS,Kiran Naqvi, MD

January 2nd 2026

Explore real-world outcomes of Luspatercept and second-line ESAs in treating low-risk MDS, revealing promising response rates and treatment insights.

RWO 1L lupatercept vs 2L ESA

BySaulius Girnius, MD,Jamie Koprivnikar, MD,Aditi Shastri, MBBS,Brittany Ragon, MD,Jamile Shammo, MD, FASCP, FACP,Michael Haddadin, MBBS,Kiran Naqvi, MD

January 2nd 2026

Encountering an error while trying to access content? Discover solutions to troubleshoot and resolve connectivity issues effectively.

‘Seamlessly’ Integrating Bioimpedance Spectroscopy Into Clinical Workflows

ByKandance P. McGuire, MD, FACS

January 1st 2026

Frequent follow-up to determine if lymphedema has developed is necessary to catch it early and begin rehabilitation processes.

Bioimpedance Spectroscopy is Allowing for Lymphedema Reduction in Breast Cancer

ByKandance P. McGuire, MD, FACS

December 31st 2025

The use of bioimpedance spectroscopy takes under 2 minutes and can help detect lymphedema before symptoms appear.

Interpreting Overall Survival and Subgroup Outcomes in MATTERHORN: Where DFLOT Shows Strength and Where Questions Remain

ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD

December 29th 2025

Experts discuss the significance of event-free survival and overall survival in cancer trials, emphasizing patient quality of life and treatment decisions.

Interpreting Endpoints and Pathologic Response: Applying EFS, PCR, and Biomarkers in Perioperative Decision Making

ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD

December 29th 2025

Experts discuss the significance of event-free survival and overall survival in cancer trials, emphasizing the importance of patient quality of life.

‘Relatively Low’ AEs Noted With Durvalumab/FLOT in Gastric/GEJ Cancer

ByYelena Y. Janjigian, MD

December 28th 2025

Clinicians who are experienced with immunotherapy, like durvalumab, can easily identify and manage AEs associated with treatment for gastric/GEJ cancer.

Durvalumab/FLOT Cemented as New SOC in Gastric/GEJ Cancers

ByYelena Y. Janjigian, MD

December 27th 2025

Based on results from the MATTERHORN study of durvalumab/FLOT in gastric/GEJ cancers, the regimen should be considered a new SOC.

Behind the MATTERHORN Trial of Durvalumab/FLOT in Gastric/GEJ Cancer

ByYelena Y. Janjigian, MD

December 26th 2025

Yelena Y. Janjigian, MD, provides the background of the MATTERHORN trial, showcasing the importance of durvalumab plus FLOT in gastric/GEJ cancers.

High-Risk Patient Populations and Therapy Selection for EGFR-Mutant mNSCLC

ByMartin Dietrich, MD, PhD,Danny Nguyen, MD,Joshua K. Sabari, MD,Alexander Spira, MD, PhD, FACP, FASCO

December 24th 2025

Oncologists discuss effective strategies for safely implementing combination therapies while managing adverse events to enhance patient outcomes.

CNS Disease and Intracranial Management in EGFR-Mutant mNSCLC

ByMartin Dietrich, MD, PhD,Danny Nguyen, MD,Joshua K. Sabari, MD,Alexander Spira, MD, PhD, FACP, FASCO

December 24th 2025

Experts discuss the efficacy of amivantamab and lazertinib in treating EGFR mutations, highlighting improved outcomes and reduced CNS metastases.

Why is Lymphedema Detected So Late in Breast Cancer?

ByKandance P. McGuire, MD, FACS

December 24th 2025

Kandance P. McGuire, MD, FACS, breaks down what lymphedema is and why it may be detected later.

DFLOT Implementation: Surgical Timing, Patient Selection, and the Evolving Role of Adjuvant Immunotherapy

ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD

December 22nd 2025

Doctor Fontaine discusses the importance of patient selection for preoperative chemotherapy and the effectiveness of immune checkpoint inhibitors in surgery outcomes.

MATTERHORN Trial Design and DFLOT Adoption: Integrating Immunotherapy Into Perioperative Practice

ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD

December 22nd 2025

Experts discuss the challenges and strategies in managing patients with inadequate responses to preoperative cancer treatments, emphasizing the need for clinical trials.

Introducing COPERNICUS: Clinical Gaps and the Rationale for a New First-Line Strategy

ByEdgardo Santos, MD, FACP, FASCO

December 22nd 2025

This opening section introduces the COPERNICUS study and frames it within the evolving treatment landscape for EGFR-mutated metastatic non–small cell lung cancer.

ZUMA-7 Final Analysis: Key Efficacy and Safety Findings

ByMatthew A. Lunning, DO,Loretta J. Nastoupil, MD,Brian T. Hill, MD, PhD,Christopher R D'Angelo, MD,David Miklos, MD, PhD,Nathan Denlinger, DO, MS ,Amitkumar Mehta, MD

December 19th 2025

TRANSFORM + Long-Term Follow-Up ASH 2025 Insights: Durability, Survival, and Safety Updates

ByMatthew A. Lunning, DO,Loretta J. Nastoupil, MD,Brian T. Hill, MD, PhD,Christopher R D'Angelo, MD,David Miklos, MD, PhD,Nathan Denlinger, DO, MS ,Amitkumar Mehta, MD

December 19th 2025

Sequencing Targeted Therapies and Approaches for Genomic Versus Non-Genomic Cases

ByHeather McArthur, MD, MPH,Sarah Sammons, MD,Ruta Rao, MD,William J. Gradishar, MD,Tiffany Traina, MD, FASCO

December 19th 2025

Panelists discuss how sequencing targeted therapies after CDK4/6 inhibitors differs for patients with actionable mutations versus those without, incorporating evidence for rechallenge and combination strategies.

Clinical Implications of COMMANDS Trial

BySaulius Girnius, MD,Jamie Koprivnikar, MD,Aditi Shastri, MBBS,Brittany Ragon, MD,Jamile Shammo, MD, FASCP, FACP,Michael Haddadin, MBBS,Kiran Naqvi, MD

December 19th 2025

FACE-OFF: Low-Risk MDS ASH 2025

Evolving Definitions and Risk Gaps in High-Risk Smoldering Multiple Myeloma

ByLarry Anderson, MD, PhD,Caitlin Costello, MD,Laahn Foster, MD

December 19th 2025

Explore the evolving landscape of high-risk smoldering myeloma treatment options and the challenges in patient management and risk assessment.

Oral Hypomethylating Agents: Adherence, Real-World Data, and Expanding Use

ByAmer Zeidan, MBBS ,Ralph V. Boccia, MD, FACP ,Salman Fazal, MD ,Susan Granato, CRNP ,Aditi Shastri, MBBS

December 19th 2025

Explore the differences between bispecific antibodies and CAR T-cell therapy, highlighting their unique benefits and administration processes in cancer treatment.

Bispecific Antibodies vs CAR T-Cells: Mechanistic and Practical Distinctions

BySundar Jagannath, MBBS,Ajay Nooka, MD, MPH, FACP,Mohan Krishnamachary, MD,Nisha Joseph, MD,Donna Catamero, MSN, ANP-BC, OCN, CBCN

December 19th 2025

Explore the differences between bispecific antibodies and CAR T-cell therapy, highlighting their unique benefits and administration processes in cancer treatment.

Evolving Evidence for CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma

ByKrina Patel, MD, MSc ,Noopur Raje, MD,Gurbakhash Kaur, MD

December 19th 2025

Panelists discuss how pivotal trials and real-world evidence have reinforced CAR T-cell therapy’s high response rates, deep remissions, and durable outcomes in relapsed/refractory multiple myeloma.

Introduction and Phase 3 COMMANDS Trial

BySaulius Girnius, MD,Jamie Koprivnikar, MD,Aditi Shastri, MBBS,Brittany Ragon, MD,Jamile Shammo, MD, FASCP, FACP,Michael Haddadin, MBBS,Kiran Naqvi, MD

December 19th 2025

FACE-OFF: Low-Risk MDS ASH 2025

Emerging Therapeutic Strategies in High-Risk Smoldering Multiple Myeloma

ByLarry Anderson, MD, PhD,Caitlin Costello, MD,Laahn Foster, MD

December 19th 2025

Explore the evolving treatment strategies for high-risk smoldering multiple myeloma, emphasizing early intervention and recent clinical advancements.

Introduction and Genomic Testing in Advanced Breast Cancer

ByHeather McArthur, MD, MPH,Sarah Sammons, MD,Ruta Rao, MD,William J. Gradishar, MD,Tiffany Traina, MD, FASCO

December 19th 2025

Panelists discuss how integrating both tissue and liquid genomic testing at diagnosis and progression improves detection of tumor heterogeneity and informs personalized treatment decisions in metastatic breast cancer.

Videos

Integrating PD-L1 Testing and Practical Implications for DFLOT Adoption

Unmet Clinical Needs Driving Early Intervention in High-Risk Smoldering Multiple Myeloma

Comparing the Approved BCMA Bispecifics: Efficacy, Toxicity, and Treatment Burden

Practical Implementation of Oral HMAs in MDS/CMML: Safety, Monitoring, and Coordination

Insights into RWO 1L lupatercept vs 2L ESA

RWO 1L lupatercept vs 2L ESA

‘Seamlessly’ Integrating Bioimpedance Spectroscopy Into Clinical Workflows

Bioimpedance Spectroscopy is Allowing for Lymphedema Reduction in Breast Cancer

Interpreting Overall Survival and Subgroup Outcomes in MATTERHORN: Where DFLOT Shows Strength and Where Questions Remain

Interpreting Endpoints and Pathologic Response: Applying EFS, PCR, and Biomarkers in Perioperative Decision Making

‘Relatively Low’ AEs Noted With Durvalumab/FLOT in Gastric/GEJ Cancer

Durvalumab/FLOT Cemented as New SOC in Gastric/GEJ Cancers

Behind the MATTERHORN Trial of Durvalumab/FLOT in Gastric/GEJ Cancer

High-Risk Patient Populations and Therapy Selection for EGFR-Mutant mNSCLC

CNS Disease and Intracranial Management in EGFR-Mutant mNSCLC

Why is Lymphedema Detected So Late in Breast Cancer?

DFLOT Implementation: Surgical Timing, Patient Selection, and the Evolving Role of Adjuvant Immunotherapy

MATTERHORN Trial Design and DFLOT Adoption: Integrating Immunotherapy Into Perioperative Practice

Introducing COPERNICUS: Clinical Gaps and the Rationale for a New First-Line Strategy

ZUMA-7 Final Analysis: Key Efficacy and Safety Findings

TRANSFORM + Long-Term Follow-Up ASH 2025 Insights: Durability, Survival, and Safety Updates

Sequencing Targeted Therapies and Approaches for Genomic Versus Non-Genomic Cases

Clinical Implications of COMMANDS Trial

Evolving Definitions and Risk Gaps in High-Risk Smoldering Multiple Myeloma

Oral Hypomethylating Agents: Adherence, Real-World Data, and Expanding Use

Bispecific Antibodies vs CAR T-Cells: Mechanistic and Practical Distinctions

Evolving Evidence for CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma

Introduction and Phase 3 COMMANDS Trial

Emerging Therapeutic Strategies in High-Risk Smoldering Multiple Myeloma

Introduction and Genomic Testing in Advanced Breast Cancer

Trending on CancerNetwork

Collaboration May Expedite ctDNA Use and Inform Adjuvant Rectal Cancer Care

Mobile Unit Seeks to Bolster Prostate Cancer Testing Among At-Risk Groups

Interpreting Baseline Profiles and PFS Outcomes in High-Risk Smoldering Multiple Myeloma

Study Population and Cohort Design: Reflecting Real World EGFR Mutant NSCLC

Addressing the Complex Survivorship Landscape for Older Patients With Breast Cancer